

COVID-19 - is the ACE2 just a foe?

Jakovac, Hrvoje

Source / Izvornik: **American Journal of Physiology-Lung Cellular and Molecular Physiology, 2020, 318, L1025 - L1026**

Journal article, Accepted version

Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)

<https://doi.org/10.1152/ajplung.00119.2020>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:184:738446>

Rights / Prava: [In copyright](#) / [Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2025-03-13**



Repository / Repozitorij:

[Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository](#)



LETTER TO THE EDITOR | *The Pathophysiology of COVID-19 and SARS-CoV-2 Infection*

COVID-19: is the ACE2 just a foe?

 **Hrvoje Jakovac**

Department of Physiology and Immunology, Medical Faculty, University of Rijeka, Rijeka, Croatia

Submitted 31 March 2020; accepted in final form 31 March 2020

TO THE EDITOR: I read with great interest and pleasure the recent Letter “Covid-19 infection and mortality: a physiologist’s perspective enlightening clinical features and plausible interventional strategies” by Abassi and colleagues (1). In the article, the authors suggested blockage of angiotensin-converting enzyme 2 (ACE2) as a potential strategy for mitigating the clinical picture and reducing mortality in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected subjects. Because the SARS-CoV-2 virus uses ACE2 as a receptor, this approach could be promising to prevent virus entry into the pneumocytes. But, ACE2 inhibition in COVID-19 patients with already developed symptoms could even be detrimental due to the consequent decrease in the production of angiotensin 1–7, which, as has been stated by the authors, shows anti-inflammatory and antifibrotic activity via the Mas receptor. Regarding that, the authors also mentioned that the depletion of ACE2 by SARS-CoV-2 binding may be responsible for the more severe clinical presentation of COVID-19 in the group of high-risk patients (1). Indeed, previous studies showed the protective effect of ACE2 in the animal models of acute respiratory distress syndrome (ARDS) (4, 7, 14), while angiotensin II was found to be a harmful molecule, causing pulmonary edema and fibrosis (8). So, inhibition of ACE2 could lead to reduced clearance of the harmful molecule, while the protective one would be insufficiently produced. Moreover, suggestions considering ACE2 induction as a possible therapeutic strategy for COVID-19 have recently emerged (11). Besides, an increased level of soluble ACE2 isoform, as a consequence of preexisting disease (such as inflammatory bowel diseases), has been assumed as a possible protective factor, acting by intercepting viral particles (9, 12). Interestingly, ACE2 is expressed in the respiratory tract only moderately compared with intestinal epithelia (2, 3), but respiratory symptomatology is incomparably more severe than intestinal, although among COVID-19 patients up to 50% of stool specimens were SARS-CoV-2 positive (10), and some patients remained stool-positive after respiratory samples were negative (13). These observations give rise to the possibility that a higher proportion of “intact” ACE2 molecules provide sufficient protection during infection, and suggest that the role of ACE2 during COVID-19 pathogenesis should be considered relative to viral load.

By all accounts, in the context of SARS-CoV-2 infection, ACE2 could justifiably be referred to as a double-edged sword. Regarding that, it is worth distinguishing “passive” ACE2 expression, which is undoubtedly the main doorway for viral entry, and total ACE2 activity, which seems to be protective. The situation could be further complicated if the SARS-CoV-2 is capable to shed catalytically active ACE2 ectodomains, as is the case with SARS-CoV (5, 6), which would lead to the releasing of active ectodomains in the systemic circulation. If so, in addition to its potential diagnostic relevance, an increase in plasma ACE2 activity may diminish systemic effects of angiotensin II, impairing thus hemodynamics and renal function in critically ill COVID-19 patients.

Withal, it should be emphasized that angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) are differently related to ACE2: in contrast to ARBs, ACE-Is deplete its substrate and consequently reduce the production of the final anti-inflammatory product. Moreover, by blocking the receptors, ARBs could divert a larger proportion of generated angiotensin II towards ACE2. These assumptions encourage more detailed stratification of clinical presentation and outcome among COVID-19 patients receiving renin-angiotensin system (RAS) modulating drugs.

Finally, it is reasonable to assume that different ACE2 gene polymorphisms could underlie a huge variety of COVID-19 clinical presentation and outcome, as well as a propensity for infection.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author.

AUTHOR CONTRIBUTIONS

H.J. drafted manuscript; edited and revised manuscript; and approved final version of manuscript.

REFERENCES

1. Abassi ZA, Skorecki K, Heyman SN, Kinaneh S, Armaly Z. Covid-19 infection and mortality: a physiologist’s perspective enlightening clinical features and plausible interventional strategies. *Am J Physiol Lung Cell Mol Physiol*. In press. doi:10.1152/ajplung.00097.2020.
2. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* 203: 631–637, 2004. doi:10.1002/path.1570.
3. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. *FEBS Lett* 532: 107–110, 2002. doi:10.1016/S0014-5793(02)03640-2.
4. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature* 436: 112–116, 2005. doi:10.1038/nature03712.

Address for correspondence: H. Jakovac, Department of Physiology and Immunology, Medical Faculty, University of Rijeka, Brace Branchetta 20, 51000 Rijeka, Croatia (e-mail: hrvoje.jakovac@medri.uniri.hr).

5. **Jia HP, Look DC, Tan P, Shi L, Hickey M, Gakhar L, Chappell MC, Wohlford-Lenane C, McCray PB Jr.** Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. *Am J Physiol Lung Cell Mol Physiol* 297: L84–L96, 2009. doi:[10.1152/ajplung.00071.2009](https://doi.org/10.1152/ajplung.00071.2009).
6. **Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ.** Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). *J Biol Chem* 280: 30113–30119, 2005. doi:[10.1074/jbc.M505111200](https://doi.org/10.1074/jbc.M505111200).
7. **Li Y, Zeng Z, Cao Y, Liu Y, Ping F, Liang M, Xue Y, Xi C, Zhou M, Jiang W.** Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF- κ B signaling pathways. *Sci Rep* 6: 27911, 2016. doi:[10.1038/srep27911](https://doi.org/10.1038/srep27911).
8. **Marshall RP, Gohlke P, Chambers RC, Howell DC, Bottoms SE, Unger T, McAnulty RJ, Laurent GJ.** Angiotensin II and the fibroproliferative response to acute lung injury. *Am J Physiol Lung Cell Mol Physiol* 286: L156–L164, 2004. doi:[10.1152/ajplung.00313.2002](https://doi.org/10.1152/ajplung.00313.2002).
9. **Monteleone G, Ardizzone S.** Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? *J Crohn's Colitis*. In press. doi:[10.1093/ecco-jcc/jjaa061](https://doi.org/10.1093/ecco-jcc/jjaa061).
10. **Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W.** Detection of SARS-CoV-2 in different types of clinical specimens. *JAMA*. In press. doi:[10.1001/jama.2020.3786](https://doi.org/10.1001/jama.2020.3786).
11. **Wu Y.** Compensation of ACE2 function for possible clinical management of 2019-nCoV-induced acute lung injury. *Virology*. In press. doi:[10.1007/s12250-020-00205-6](https://doi.org/10.1007/s12250-020-00205-6).
12. **Battle D, Wysocki J, Satchell K.** Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? *Clin Sci (Lond)* 134: 543–545, 2020. doi:[10.1042/CS20200163](https://doi.org/10.1042/CS20200163).
13. **Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H.** Evidence for gastrointestinal infection of SARS-CoV-2. *Gastroenterology*. In press. doi:[10.1053/j.gastro.2020.02.055](https://doi.org/10.1053/j.gastro.2020.02.055).
14. **Ye R, Liu Z.** ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway. *Exp Mol Pathol* 113: 104350, 2020. doi:[10.1016/j.yexmp.2019.104350](https://doi.org/10.1016/j.yexmp.2019.104350).

